Publications

=


Peer-review publications

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T cell Therapy. Spranger S, Dai D, Horton B, Gajewski TF. Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.

Density of immunogenic antigens does not explain the presence or absence of the T cell-inflamed tumor microenvironment in melanoma. Spranger S*, Luke JJ*, Bao R, Zha Y, Hernandez K, Li Y, Gajewski AP, Andrade J, Gajewski TF. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. Epub 2016 Nov 11.

Lymphatic vessels regulate immune microenvironments in human and murine melanoma. Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA. J Clin Invest. 2016 Sep 1;126(9):3389-402. doi: 10.1172/JCI79434. PubMed PMID: 27525437; PubMed Central PMCID: PMC5004967.

Molecular Drivers of the Non-T Cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg GD, Gajewski TF. Cancer Immunol Res. 2016 Jul;4(7):563-8. doi: 10.1158/2326-6066.CIR-15-0274. PubMed PMID: 27197067; PubMed Central PMCID: PMC4943758.

Engineering Active IKKβ in T Cells Drives Tumor Rejection. Evaristo C, Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML. J Immunol. 2016 Apr 1;196(7):2933-8. doi: 10.4049/jimmunol.1501144. PubMed PMID: 26903482; PubMed Central PMCID: PMC4799771.

Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li H, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi LG, Davies MA, Hwu P, Cancer Discov. 2015 Dec 8.

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Spranger S, Bao R, and Gajewski TF, Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11.

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung M, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre M, Gajewski TF, Immunity. 2014 Nov 20;41(5):830-42. doi: 10.1016/j.immuni.2014.10.017. Epub 2014 Nov 5.

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. Spranger S, Koblish H, Horton B, Scherle P, Newton R, Gajewski TF, J Immunother Cancer. 2014 Feb 18;2:3. doi: 10.1186/2051-1426-2-3. eCollection 2014.

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF, Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504.

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, Dörken B, Lenz P, Lenz G, Schendel DJ, Krappmann D, Cancer Cell. 2012 Dec 11;22(6):825-37. doi: 10.1016/j.ccr.2012.11.002.

T cell receptor-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Spranger S, Jeremias I, Wilde S, Leisegang M, Stärk L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ and Frankenberger B, Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.

NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. Spranger S, Frankenberger B, Schendel DJ., J Transl Med. 2012 Feb 25;10:30. doi: 10.1186/1479-5876-10-30.

The CD6 scavenger receptor is differentially expressed on a CD56dim NK cell subpopulation and contributes to NK-derived cytokine and chemokine secretion. Braun M, Müller B, Ter Meer D, Raffegerst S, Simm B, Wilde S, Spranger S, Ellwart J, Mosetter B, Umansky L, Lerchl T, Schendel DJ, Falk CS, J Innate Immun. 2011;3(4):420-34. doi: 10.1159/000322720. Epub 2010 Dec 18.

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, Schendel D J, J Clin Invest. 2010 Nov;120(11):3869-77. doi: 10.1172/JCI43437. Epub 2010 Oct 11.

Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. J Transl Med. 2010 Sep 28;8:90. doi: 10.1186/1479-5876-8-90.

Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ, Frankenberger B, J Immunol. 2010 Jul 1;185(1):738-47. doi: 10.4049/jimmunol.1000060. Epub 2010 May 28.

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Wilde S, Sommermeyer D, Frankenberger B, Schiemann M, Milosevic S, Spranger S, Pohla H, Uckert W, Busch DH, Schendel DJ, Blood. 2009 Sep 3;114(10):2131-9. doi: 10.1182/blood-2009-03-209387. Epub 2009 Jul 8.

Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Messerli SM, Kasinathan RS, Morgan W, Spranger S, Greenberg RM, Mol Biochem Parasitol. 2009 Sep;167(1):54-9. doi: 10.1016/j.molbiopara.2009.04.007. Epub 2009 May 3.

*authors contributed equally

 

Reviews, Commentaries and book chapters
 

Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem. Spranger S. Trends Immunol. 2016 Jun;37(6):349-51. doi: 10.1016/j.it.2016.04.008. PubMed PMID: 27166403.

MYC - a thorn in the side of cancer immunity. Spranger S, Gajewski TF, Kline J. Cell Res. 2016 Jun;26(6):639-40. doi: 10.1038/cr.2016.50. PubMed PMID: 27113275; PubMed Central PMCID: PMC4897180.

Tumor-intrinsic oncogene pathways mediating immune avoidance Spranger S and Gajewski TF, Oncoimmunology. 2015 Aug 31;5(3):e1086862. eCollection 2016 Mar. Review.

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Spranger S. 2016 Aug;28(8):383-91. doi: 10.1093/intimm/dxw014. Review. PubMed PMID: 26989092; PubMed Central PMCID: PMC4986232.

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Spranger S, Sivan A, Corrales L, Gajewski TF. Adv Immunol. 2016;130:75-93. doi: 10.1016/bs.ai.2015.12.003. PubMed PMID: 26923000; PubMed Central PMCID: PMC4864964.

Targeting IDO1 and Other Tryptophan Dioxygenases For Cancer Immunotherapy. Zhai L, Spranger S, Binder D, Gritsina G, Lauing K, Giles F, Wainwright D, Clin Cancer Res. 2015 Dec 15;21(24):5427-33.

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. Spranger S and Gajewski TF, J Immunother Cancer. 2015 Sep 15;3:43. doi: 10.1186/s40425-015-0089-6. eCollection 2015.

Rational combinations of immunotherapeutics that target discrete pathways. Spranger S and Gajewski TF, J Immunother Cancer. 2013 Sep 23;1:16. doi: 10.1186/2051-1426-1-16. eCollection 2013.

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S, Curr Opin Immunol. 2013 Apr;25(2):268-76. doi: 10.1016/j.coi.2013.02.009. Epub 2013 Apr 8.

 

Full publication list >>